Its successor bosentan (Tracleer; Actelion, Allschwil, Switzerland), also a mixed ETA/ETB antagonist, was the first in class to be introduced into the clinic, initially for the treatment of pulmonary arterial hypertension (PAH) (Rubin et al., 2002). Here, EDNRA is linked to pulmonary arterial hypertension.